Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish

Meclozine has been developed as an inhibitor of fibroblast growth factor receptor 3 (FGFR3) to treat achondroplasia (ACH). Extracellular signal regulated kinase (ERK) phosphorylation was attenuated by meclozine in FGF2-treated chondrocyte cell line, but the site of its action has not been elucidated...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemoto, Genta, Matsushita, Masaki, Okamoto, Takaaki, Ito, Toshinari, Matsuura, Yuki, Takashima, Chieko, Chen-Yoshikawa, Toyofumi Fengshi, Ebi, Hiromichi, Imagama, Shiro, Kitoh, Hiroshi, Ohno, Kinji, Hosono, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804316/
https://www.ncbi.nlm.nih.gov/pubmed/35118060
http://dx.doi.org/10.3389/fcell.2021.694018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804316/
https://www.ncbi.nlm.nih.gov/pubmed/35118060
http://dx.doi.org/10.3389/fcell.2021.694018

Ejemplares similares